Diabetic Treatment Group Research Articles

Validation of Blood Glucose and Lipid-Lowering Effect of Solvent Fractions of the Crinum Abyssinicum Shoot Tips in Streptozotocin-Induced Diabetic Mice.

Diabetes mellitus prevalence has reached epidemic levels despite the existence of contemporary treatments. People thus started looking at the possible therapeutic value of natural therapies. Crushed shoot tips of Crinum abyssinicum (Amaryllidaceae) are mixed with water in Ethiopia to treat diabetes, yet this practice is not well supported by science. In this experiment, mice models were used to verify the blood sugar and lipid-lowering benefits of solvent fractions of C. abyssinicum shoot tips. In a single-dose treated Streptozotocin (STZ)-induced diabetic model, mice were randomly grouped into eleven categories which include diabetic negative control, diabetic positive control, and 9 diabetic treatment groups. In repeated daily doses treated STZ-induced model, Mice were divided into 6 groups which included normal and diabetic negative control (TW80), diabetic positive control (5mg/kg glibenclamide), and three diabetic treatment groups 100, 200, and 400mg/kg). Finally, blood glucose, lipid level, and body weight were examined. In the single-dose treated diabetic model, there was a significant blood glucose reduction at 200 and 400mg/kg doses of aqueous fraction and glibenclamide starting from the sixth-hour post-administration unlike ethyl acetate and chloroform fraction compared to baseline and negative control. In repeated daily dose-treated diabetic mice, all three doses (100, 200, and 400mg/kg of aqueous fraction) resulted in a substantial reduction (P < .001) in blood glucose compared to baseline and negative control on the seventh day and 14th day. Besides the AQF shows improvement in lipid levels and body weight parameters. The results of the study demonstrated that C. abyssinicum shoot tip fractions have the greatest potential to lower blood sugar and lipid levels, supporting conventional claims for the treatment of diabetes.

Protective effect of Moringa oleifera leaves extract on cardiac fibrosis of streptozotocin-induced diabetic rats

Diabetes mellitus (DM) is a metabolic disease characterized by chronic hyperglycemia that induces excessive reactive oxygen species (ROS) production and causes oxidative stress. Diabetic cardiomyopathy is a diabetic complication characterized by structural and functional changes of the myocardium. Fibrosis is one of the pathological features of diabetic cardiomyopathy. Moringa oleifera leaves have been reported to possess antidiabetic and antioxidant activities which could prevent diabetic complications such as cardiomyopathy. A previous study reported that M. oleifera leaves extract have protective effects to the kidneys and liver of rats exposed to oxidative stress. This study aimed to investigate the protective effect of the M. oleifera leaves extract on cardiac fibrosis of rats induced by streptozotocin (STZ). This was an experimental study using a posttest-only control group design. Thirty-three male Wistar rats were randomly divided into three groups i.e. normal control group (Group 1) were administered normal saline, diabetic control group (Group 2) were administered normal saline, and diabetic treatment group (Group 3) were administered M. oleifera leaves extract. Diabetes induction of rats was conducted by intraperitoneally injection of STZ at dose of 45 mg/kg BW. The M. oleifera leaves extract at a dose of 1000 mg/kg BW was administered orally one time a day for 28 days. Statistical analysis was performed using the Kruskal-Wallis test followed by Mann Whitney. A significant difference in cardiac fibrosis occurrence between three groups was observed (p &lt; 0.05). No cardiac fibrosis was observed in normal control group, meanwhile cardiac fibrosis was observed in all rats (9 rats) of the diabetic control group (G2). Only 2 rats in the treatment group (G3) had cardiac fibrosis. In conclusion, M. oleifera leaves extract can inhibit cardiac fibrosis in STZ-induced diabetic rats.

The Japanese version of Problem Areas in Diabetes Scale: a clinical and research tool to assess emotional functioning among people with diabetes.

The purpose of this study was to develop the Japanese version of the Problem Areas in Diabetes (PAID) scale, a measure of emotional adjustment to diabetes that has been translated into Japanese by our group. A total of 418 Japanese people with diabetes attending our outpatient clinic participated (n = 65 type 1 and n = 353 type 2). We assessed the internal reliability of the PAID, examined correlations of the PAID with conceptually related psychosocial constructs, evaluated mean differences in the PAID between diabetes treatment groups, and examined correlations of the PAID with diabetes self-care behaviours and selected treatment outcomes. Results showed that the PAID had excellent reliability (Cronbach alpha = 0.934). The PAID correlated significantly with the Diabetes Treatment Satisfaction Questionnaire (r = -0.593, p < 0.0001) and the positive wellbeing (r = -0.396, p < 0.0001), negative wellbeing (r = -0.640, p < 0.0001) and energy (r = -0.444, p < 0.0001) subscales of the Wellbeing Questionnaire. Adherence to diet was negatively correlated with PAID score (r = -0.263, p < 0.0001). The frequency of recent hypoglycemia and number of chronic complications (retinopathy, nephropathy and neuropathy) were positively correlated with PAID scores. PAID was weakly correlated with HbA1c (r = 0.13, p = 0.01). In conclusion, the Japanese version of the PAID demonstrated good internal reliability and evidence of concurrent and discriminant validity. The PAID measures the impact of diabetes, diabetes treatment and treatment outcomes on the emotions of people with diabetes. The results provide encouraging evidence for the clinical utility of the PAID in Japanese people with diabetes.

Validation of Antidiabetic and Antihyperlipidemic Effects of 80% Methanolic Extract of the Lonchocarpus laxiflorus Leaves in Streptozotocin-Induced Diabetic Swiss Albino Mice.

Diabetes mellitus (DM) is a chronic endocrine disorder that requires long-term treatment. In Ethiopian traditional medicine practice, plants have been provided with a vital role in fighting human and animal diseases since ancient times. The aqueous extract of Lonchocarpus laxiflorus (L. laxiflorus) leaves has been consumed for treating diabetes mellitus without confirming its safety and efficacy scientifically. This experiment aimed to evaluate the safety and antidiabetic efficacy of the leaf extract of L. laxiflorus in mice models. The crude extraction was conducted using a cold maceration technique and 80% methanol solvent. Normoglycemic, oral glucose-loaded, and streptozotocin-induced (STZ) diabetic models were employed. Male Swiss albino mice were randomly grouped into five categories( with six mice per group during normoglycemic, oral glucose-loadingtest as a negative control, positive control, and three treatment groups. In STZ-induced diabetic models, the groups include normal and diabetic negative control, diabetic positive control, and three diabetic treatment groups. The negative control groups received vehicles, the positive control received 5 mg/kg glibenclamide, and the treatment groups received the crude extract at 100, 200, and 400 mg/kg doses, respectively. Up to 2000 mg/kg crude extract, neither signs of toxicity nor death were observed. In normoglycemic mice, there was a significant blood glucose reduction at 200 and 400 mg/kg doses starting from the 2nd h post-administration. The oral glucose load showed a significant antihyperglycemic effect at 200 and 400 mg/kg of the crude extract and glibenclamide. In STZ-induced diabetic models, the 200, 400 mg/kg crude extract, and glibenclamide showed a significant antidiabetic activity and enhancement of a good serum lipid profile. This study confirmed that the leaf of L. laxiflorus was safe and possesses antidiabetic and antidyslipidemic activities.

Ameliorative effects of half-dose saffron and chamomile combination on Psycho-endocrinological changes in a diabetic murine model.

IntroductionDiabetes mellitus is a chronic metabolic disorder with an increasing prevalence worldwide. Reduction in blood insulin level alters brain function by inducing oxidative stress with changes in dopamine and norepinephrine neurotransmission, ultimately leading to neuropsychological symptoms. The efficacy of currently available psychotropic drugs is not satisfactory. Therefore, this study was conducted to explore the beneficial effects of a combination of the natural herbs, saffron and chamomile, in treating diabetes and its resultant neuropsychological effects using a rodent model of diabetes mellitus.MethodThe rats were randomly divided in to eight groups (n = 10), healthy control (HC), diabetic control (DC) and six groups of diabetic rats treated with various concentrations and combinations of saffron and chamomile. Diabetic treatment groups individually received methanolic extract and water decoction of chamomile (30 mg/kg) and saffron (10mg/kg) and their combined half doses (saffron 5mg/kg and chamomile 15mg/kg) for two weeks. Open field test (OFT) and forced swim test (FST) were used to measure the anxiolytic and antidepressant effects of herbs, respectively. Finally, biochemical, and neurochemical estimations were made.ResultsThe present study suggests the therapeutic effects of herbs especially in co-administrated decoction, against diabetes with improved antioxidant profile and enhanced levels of dopamine and norepinephrine. Anxiolytic and antidepressant effects were evident with improvements in the OFT and FST. Examination of the cortex of the diabetic group revealed cellular damage and tangle formation, which indicates advanced stages of dementia.ConclusionThis study shows that the use of a combination of saffron and chamomile improves diabetes control and reduces its related psychiatric effects.

Anti-diabetic effects of fullerene C60 nanoparticle mediated by its anti-oxidant activity in the pancreas in type 1 diabetic rats

The present study aims to examine the anti-diabetic effects of fullerene C60 nanoparticle, as an anti-oxidant compound, on serum glucose level, body weight, food and water intake, and pancreatic oxidative stress in the rats with type 1 diabetes. Diabetes mellitus was induced by single intravenous injection of streptozotocine (45 mg/kg) into the tail vein of the rats. Four groups of rats were divided as follow: normal, normal treatment, diabetic, and diabetic treatment groups. Normal treatment and diabetic treatment groups received intra-orally fullerene (1 mg/ kg/daily) up to day 60 following streptozotocine injection. Oxidative stress markers in the pancreas were evaluated on day 60 after inducing diabetes mellitus. Injection of streptozotocine significantly increased serum glucose level as well as food and water intake on all experimental days; it decreased body weight on day 60. Streptozotocine increased MDA level and decreased GSH level and SOD activity in the pancreas. Fullerene significantly decreased food and water intake and increased body weight as compared with the diabetic group. Fullerene also could normalize the pancreatic MDA and GSH markers. The present study suggested that fullerene can decrease diabetic symptoms via its anti-oxidant activity in the pancreas in the rats with type 1 diabetes mellitus.

Diabetes severity measured by treatment control status and number of anti-diabetic drugs affects presenteeism among workers with type 2 diabetes

BackgroundThe number of people with diabetes is increasing and resulting in major economic losses. Presenteeism accounts for the majority of economic losses, so measures against presenteeism are important. This study investigated the relationship between severity of type 2 diabetes and presenteeism.MethodsA cross-sectional study was conducted among workers over 40 years of age. Participants were classified as normal group or diabetic treatment group using their medical examination results and health insurance claims data. Diabetic treatment groups were described by degree of treatment control: Good (HbA1c < 7%), Intermediate (7% ≤ HbA1c < 8%), and Poor (8% ≤ HbA1c). Therapy type was also divided into monotherapy and combination therapy. Logistic regression analysis was performed to predict presenteeism loss using the Quantity and Quality method.ResultsData on 13,271 workers were analyzed. Presenteeism loss was significantly higher in all treatment control groups compared with the normal group, particularly for the intermediate and poor control groups. The monotherapy group did not differ from the normal group, but presenteeism loss was significantly higher in the combination therapy group than the normal group.ConclusionsPresenteeism loss in workers with diabetes may be affected by diabetes severity, and even if treatment control were good, presenteeism loss could occur when the number of anti-diabetic drugs was high. Therefore, it is important to provide early intervention and continuous support as a preventive measure against not only diabetes and diabetes-related complications but also presenteeism.

Dietary supplementation of mustard oil reduces blood glucose levels by triggering insulin receptor signaling pathway

Dietary fatty acids can alter membrane fatty acid composition with the consequent change in the action of various receptors. Incorporation of mustard oil was found to increase insulin secretion, reduce blood glucose levels, and increase the expression of glucose transporter gene 4 (Glut4). Three-week-old male Wistar rats were fed with 8% lipid-inclusive isocaloric mash diet. There were non-diabetic control (NDC) and diabetic control (DC) groups fed with ghee, and similarly non-diabetic (NDT) and diabetic treatment (DT) groups fed with mustard oil. Streptozotocin (STZ) was administered intraperitoneally once at a dose rate of 40 mg/kg bodyweight for the induction of diabetes. Blood glucose was estimated using glucometer periodically. Lipids were extracted from mustard oil and in tissue samples, and fatty acid estimation was done using gas chromatography (GC). Gene expression of 84 genes related to diabetes was measured in muscle tissue using Qiagen™ RT2 polymerase chain reaction (PCR) profiler array. The real-time PCR data obtained as threshold cycle (Ct) values were analyzed using Ingenuity Pathway Analysis® (IPA®) software. After induction of diabetes by day 30, the average glucose levels were above 500 mg/dL in diabetic groups, but for the mustard oil treatment group, they were reduced to 337 mg/dL by the 60 days of treatment. Significantly higher levels of unsaturated fatty acids particularly linoleic acid and linolenic acid were found in mustard oil treatment groups. Insulin receptor signaling was prominent in both ghee-fed normal and mustard oil–fed diabetic treatment groups. Glucose was found to be the major upstream regulator in all the groups except for ghee-fed diabetic control group. Mustard oil inclusion in the diet reduces blood glucose levels by increased insulin receptor signaling, thereby partially reversing diabetic state in experimentally induced diabetic rats.

Effects of &lt;i&gt;Kepok&lt;/i&gt; Banana Flour on Glucose Level and Physical Performance in Type 2 Diabetic Rats

Diabetes mellitus prevalence has rapidly increased globally. Food contains high resistant starch (RS) may be used as a functional food to prevent and control diabetes mellitus. Resistant starch is high in raw bananas and its products such as flour. The study aimed to evaluate effects of Kepok banana flour on blood glucose and physical performance, especially body weight and feed intake in type 2 diabetic rats induced by nicotinamide (NA) and streptozotocin (STZ). Eight-week-old male Wistar rats weighed 150-200 g were randomly divided into nondiabetic and diabetic groups. Nondiabetic group (n=7 rats) was normal control (NC) and fed with standard diet AIN-93M (American Institute of Nutrition Rodent Diets 1993 for adult maintenance), while diabetic groups (n=7 rats each group) consisted of diabetic control (DC) which fed with standard diet and 3 diabetic treatment groups (T1-T3) which fed with AIN-93M containing kepok banana flour with 4%, 8% and 12% of RS respectively for 14 days. After 14 days, mean fasting blood glucose in group T1, T2 and T3 have lower blood glucose than DC significantly (p&lt;0.05) with the highest decrease of blood glucose was on group T3. Mean of body weight in group T1, T2, T3, and NC gained significantly compared to DC group (p&lt;0.05). Feed intake in group T1, T2, T3, and NC were less than DC significantly (p&lt;0.05). Administration of kepok banana flour with 4%, 8% and 12% of RS is able to decrease glucose level, to restore body weight loss and to reduce feed intake in STZ-NA induced type 2 diabetic rats. Kepok banana flour can be proposed as an alternative diet in the management of type 2 diabetes.

Hematobiochemical Effects of Telakucha (Coccinia Indica) in Alloxan Induced Diabetic Rats

The study was undertaken to investigate the effects of Telakucha (Cocciniaindica) on blood glucose, serum total cholesterol, hematological parameters and body weight in alloxan induced diabetic rats. In this experiment 45 rats were selected for the trial purpose. The rats were divided into 3 equal groups, each containing 15 individuals (n=15) as follows: normal control (C) group, diabetic control (DC) group and diabetic treatment (DT) group. Diabetes was induced in diabetic control (DC) and diabetic treatment (DT) group with alloxan @ 200mg/kg body weight intraperitonially. Then diabetic treatment group (DT) was treated with 10% aqueous extract of Telakucha @500 mg/kg body weight. After 42 days of treatment, Telakucha extract reduced the amount of blood glucose significantly (P&lt;0.001) in the group DT compared to DC from 32.03 ± 0.25 to 11.17 ± 0.08 mmol/L. Total cholesterol (TC) was also decreased significantly (P&lt;0.001) in group DT compared to group DC from 121.85±0.27 to 112.42±0.14 mg/dL. In hematological study, DT group showed significant (P&lt;0.001) increase in erythrocytes count and Hb (g%) content and decrease (P&lt;0.001) in total leukocyte count after 42 days of treatment in contrast with DC group. The body weight was also increased significantly (P&lt;0.001) in DT group. Based on present research it can be concluded that Telakucha (Cocciniaindica) can be used in the treatment of diabetes as an alternative to commercial medicine.&#x0D; Res. Agric., Livest. Fish.7(3): 431-438, December 2020

Gene expression of renal lactoferrin and glycemic homeostasis in diabetic rats with reference to the protective role of exogenous bovine lactoferrin

BackgroundThis study is intended to clarify the influence of exogenous bovine lactoferrin (bLf) treatment on glycemic homeostasis, gene expression, and production of lactoferrin (Lf) in rats with experimentally induced diabetes.MethodologyFifty adult male rats were used; 15 rats were used as the normal control rats (group A) and were injected an intraperitoneal (I/P) with 1 ml of isotonic saline daily for 3 months. Thirty-five rats were administered I/P injection of 60 mg of streptozotocin per kilogram body weight to induce diabetes. Thirty streptozotocin-treated rats were selected and used as diabetic rats, and they were subdivided into 2 equal groups (15 rats each): the untreated diabetic group (group B) and treated diabetic group (group C). The rats in the diabetic group were administered an I/P injection of 1 ml of isotonic saline daily for 3 months, while rats in the diabetic treatment group were administered an I/P injection of 300 mg of bLf/kg body weight/day/3 months. At the end of the experiment, blood and renal tissue samples were collected from all rats. The levels of insulin, glucose, and lactoferrin in plasma were measured. Homeostatic model assessment for insulin resistance (HOMA-IR) was performed. The numbers of Lf-mRNA copies in renal tissue were assessed using quantitative RT-PCR. To measure Lf production in renal tissue, Western blot analysis was applied.ResultsThe obtained data demonstrated that the treatment of diabetic rats with bLf maintained glycemic homeostasis at normal levels but increased the mRNA expression of renal Lf.ConclusionIn diabetic rats, bovine lactoferrin treatment offers the potential for protection against incidences of insulin resistance (IR) by stimulating the suppressed expression and production of the LTF gene.

Effects of etanercept on the apoptosis of ganglion cells and expression of Fas, TNF-α, caspase-8 in the retina of diabetic rats.

To evaluate the effects of etanercept on the expression of Fas, tumor necrosis factor-alpha (TNF-α) and caspase-8 in the early stage of the apoptotic pathway in diabetic rats, and to explore the therapeutic effect of etanercept on diabetic retinopathy. A total of 60 Sprague-Dawley (SD) rats were randomly and evenly divided into 3 groups with 20 rats each, including control group, and diabetic groups with or without treatment. Streptozotocin (STZ)-induced diabetic rats were established for diabetic groups. Blood glucose and body weight were measured weekly. All the rats were sacrificed at the 12wk after treatment. The expressions of Fas, TNF-α and caspase-8 in rat retina were quantitatively detected by PCR and Western blot. The leakage of Evan blue was adopted to measure the retinal vascular leakage quantitatively, and to compare it among different groups. TUNEL method was used to compare the amount of apoptotic bodies quantitatively in rat retina ganglion cells under electron microscope. The expressions of Fas, TNF-α and caspase-8 in each group were compared via PCR and Western blot, in which the diabetic group with treatment was lower than those without treatment (P<0.01), but all the diabetic groups were higher than the control group (P<0.01). Evans blue leakage in the diabetic treatment group was lower than those without treatment (P<0.01), but those in the control group was the lowest compared with the other two groups (P<0.01). TUNEL method showed that the apoptotic bodies of retina in the diabetic treatment group was lower than those without treatment (P<0.01), while those in the control group was the lowest compared with the other two groups (P<0.01). Etanercept can effectively reduce the expression of Fas, TNF-α and caspase-8, as well as the retinal leakage and retinal cell apoptosis in diabetic rats.

Furan induced ovarian damage in non-diabetic and diabetic rats and cellular protective role of lycopene.

In our work, furan, lycopene, and furan+lycopene treatments were applied to non-diabetic and diabetic female rats via gavage. Ovarian tissue alterations with histopathology, immunohistochemistry, malondialdehyde levels, oxidative stress parameters such as superoxide dismutase, catalase, glutathione peroxidase, glutathione-S-transferase and harmful effect on ovarian tissue DNA were evaluated in all groups for 28days. Furan caused the changes histological, ovarian cell's DNA structure, malondialdehyde levels, antioxidant enzymes activities as in a statistically significant manner in each group. Useful effect of lycopene was determined both in non-diabetic and diabetic treatment groups against furan according to the used experimental parameters. Although some histopathological alterations were seen in diabetic and non-diabetic/diabetic plus furan-treated group's ovarians, lycopene restored these variations near to normal levels in furan+lycopene treated groups for in 28days. Additionally, the results of our immunohistochemical analysis and alterations of the oxidative stress parameters results also supported these findings. Our result confirms that lycopene has protective effect and significantly altered diabetes and furan-induced toxicity in the rat ovarian tissue.

Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort.

Preservation of vision in patients with diabetes mellitus is critical. Interventions to improve glycemic control through early intensive treatment of diabetes reduce rates of severe retinopathy and preserve visual acuity. To assess the effects of prior intensive insulin treatment and risk factors on patient-reported visual function in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Cohort study of 1184 participants with type 1 diabetes from the DCCT/EDIC study (randomized clinical trial followed by an observational follow-up study) who completed the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) during EDIC years 17 through 20 (September 1, 2009, through April 30, 2014) in 28 institutions across the United States and Canada. The primary outcome was the composite NEI-VFQ-25 score. Secondary outcomes were visual acuity (measured by the Early Treatment Diabetic Retinopathy Study protocol), retinopathy level (determined by masked grading of stereoscopic color fundus photographs), and NEI-VFQ-25 subscale scores. The composite NEI-VFQ-25 scale and its subscales were scored 0 to 100, corresponding to poor to excellent function, respectively. The overall average NEI-VFQ-25 score for 1184 DCCT/EDIC participants (mean [SD] age, 52.3 [6.9] years; 48% female) with a 30-year duration of diabetes was high (all participants: median, 91.7; interquartile range [IQR], 89.7-96.9; intensive treatment [n = 605]: median, 94.7; IQR, 91.0-97.2; conventional treatment [n = 579]: median, 94.0; IQR, 88.4-96.1; P = .006 for intensive vs conventional). After adjustment for sex, age, hemoglobin A1c level, and retinopathy level at DCCT baseline, the former intensive treatment group had a significant, albeit modest, improvement in overall NEI-VFQ-25 score compared with the former conventional diabetes treatment group (median difference, -1.0; 95% CI, -1.7 to -0.3; P = .006). This beneficial treatment effect was fully attributed to the prior glycemic control in DCCT (explained treatment effect: 100%). Those with visual acuity worse than 20/100 reported the largest decline in visual function (median difference, -21.0; 95% CI, -40.5 to -1.6; P = .03). In the DCCT/EDIC cohort, patient-reported visual function remains high in both treatment groups, comparable to previous reports of overall health-related quality of life. Intensive diabetes therapy modestly improved NEI-VFQ-25 score 30 years after the start of the DCCT, the benefit underestimated owing to more nonparticipants from the conventional treatment group. Visual acuity had the greatest effect on patient-reported visual function from among all risk factors. clinicaltrials.gov Identifiers: NCT00360815 and NCT00360893.

The Effect of Diabetes Medication on Cognitive Function: Evidence from the PATH Through Life Study.

Objective. To examine the effect of diabetes treatment on change of measures of specific cognitive domains over 4 years. Research Design and Methods. The sample was drawn from a population-based cohort study in Australia (the PATH Through Life Study) and comprised 1814 individuals aged 65–69 years at first measurement, of whom 211 were diagnosed with diabetes. Cognitive function was measured using 10 neuropsychological tests. The effect of type of diabetes treatment (diet, oral hypoglycemic agents, and insulin) on measures of specific cognitive domains was assessed using Generalized Linear Models adjusted for age, sex, education, smoking, physical activity level, BMI, and hypertension. Results. Comparison of cognitive function between diabetes treatment groups showed no significant effect of type of pharmacological treatment on cognitive function compared to diet only group or no diabetes group. Of those on oral hypoglycaemic treatment only, participants who used metformin alone had better cognitive function at baseline for the domains of verbal learning, working memory, and executive function compared to participants on other forms of diabetic treatment. Conclusion. This study did not observe significant effect from type of pharmacological treatment for diabetes on cognitive function except that participants who only used metformin showed significant protective effect from metformin on domain of verbal learning, working memory, and executive function.

Reduction in self-monitoring of blood glucose in type 2 diabetes: an observational controlled study in east London.

Self-monitoring of blood glucose (SMBG) confers no benefit for many people with type 2 diabetes not being treated with insulin. It accounts for 21% of diabetes prescribing costs. To improve care quality at reduced cost for type 2 diabetes by reducing unnecessary SMBG. Non-randomised, observational controlled study in two intervention clinical commissioning groups (CCGs) and one control CCG in east London. In total, 19,602 people with type 2 diabetes not being treated with insulin were recruited from two intervention CCGs; 16,033 were recruited from a control CCG. The intervention (from 2010 to 2013) comprised implementation of a locally developed guideline, including IT support and peer feedback of performance. Data on practice prescribing SMBG testing strips were gathered using GP electronic health records. Information on costs were obtained via the ePACT electronic database. Over 4 years, in all non-insulin type 2 diabetes treatment groups, use of SMBG was reduced in the two intervention CCGs from 42.8% to 16.5%, and in the control CCG from 56.4% to 47.2%. In people on metformin alone or no treatment, intervention CCGs reduced SMBG use from 29.6% to 6.0%, and in the control CCG use dropped from 47.1% to 38.7% (P<0.001). From 2009 to 2012 the total cost of all SMBG prescribing (type 1 and type 2 diabetes, including users of insulin) was reduced by 4.9% (£62,476) in the two intervention CCGs and increased in the control CCG by 5.0% (£42,607); in England, the total cost increased by 13.5% (£19.4 million). In total, 20% (3865 of 19 602) fewer patients used SMBG in the intervention CCGs. This low-cost programme demonstrated a major reduction in unnecessary prescribing of SMBG, along with cost savings. If replicated nationally, this would avoid unnecessary testing in 340 000 people and prescribing costs that total £21.8 million.

Effect of locally produced honey on serum levels of glucose, triglyceride, cholesterol, HDL, VLDL, and LDL in alloxanized diabetic rats

Diabetes mellitus is a metabolic disorder in human and animal, particularly in pets. This study is conducted to evaluate the effect of Honey on serum levels of glucose, triglyceride, cholesterol, VLDL, LDL and HDL in experimental diabetes mellitus in rat. Male Wistar rats randomly allocated in four groups: normal, honey control, diabetic control and diabetic rats receiving honey. For creation of diabetes, a single dose of Alloxan (100 mg/kg) injected subcutaneously. After observing diabetes symptoms in groups received Alloxan, we have initiated to feed treatment group and diabetic treatment group with the equal ratio of honey and pellet. The diabetic control and control group fed only with pellet. These groups fed for 10 days. Blood samples collected from whole groups at the end of 10th day. Evaluation of the serum levels of glucose, cholesterol and LDL significantly increased between diabetic group with control group and also between treatment group and diabetic treatment group with diabetic Evaluation of the serum levels of triglyceride did not reveal statistically significant differences in diabetic treatment group and treatment group with control group, but decreased significantly compared to the diabetic control group (P<0.05). Evaluation of the serum Levels of VLDL decreased significantly in diabetic treatment group and treatment group compared with the diabetic control group (P<0.05), but did not reveal statistically difference compared with the control group. Evaluation of the serum levels of HDL did not reveal statistically significant difference between groups. Honey could be used as a natural drug for preventing diabetes mellitus disorders.

Lipid Profile and Electrolyte Composition in Diabetic Rats Treated With Leaf Extract of Musa sapientum

ABSTRACTDiabetes mellitus affects lipid levels resulting in diabetic dyslipidemia as well as electrolyte loss from the body. Musa sapientum has been reported to possess antidiabetic properties. This study assessed the lipid profile and electrolyte composition in alloxan-induced diabetic rats treated with methanol leaf extract of M. sapientum (cMEMSL). Diabetes was induced with alloxan (120 mg/kg i.p.). Seventy-five male albino rats were divided into 5 groups of 15 rats each. Group 1 was control; groups 2–5 were made diabetic and treated with 0.2 ml 0.9% NaCl, cMEMSL (250 mg/kg and 500 mg/kg), and glibenclamide (5 mg/kg), respectively, for 14 days. Blood samples were obtained from the retro orbital sinus after light anesthesia from 5 animals in each group on days 2, 7, and 14 for lipids and electrolyte analysis. Lipid profile of diabetic treated (cMEMSL and glibenclamide) animals showed significant reduction (p < .05) in total cholesterol, triglyceride, and low density lipoprotein (LDL) levels. The high density lipoprotein (HDL) level in the treatment groups increased significantly (p < .05) compared with diabetic untreated. Sodium, potassium, and phosphate ions significantly increased in all diabetic treatment groups while chloride ion significantly decreased compared with diabetic untreated. There was no significant difference in calcium and bicarbonate ion concentration in all the groups. This study has showed additional properties of Musa sapientum to include its ability to restore electrolyte balance, reduce cholesterol, triglyceride, LDL, and increase the HDL levels in diabetic animals.

Outcome of Capparis Spinosa Fruit Extracts Treatment on Liver, Kidney, Pancreas and Stomach Tissues in Normal and Diabetic Rats

Aim and objectives: Herbal drugs such as, Capparis Spinosa (CS) has been used to treat several diseases from heart and cardiovascular disorders to diabetes in traditional Iranian medicine. The present study was aimed to determine beneficiary effects of CS fruit extract on a number of tissues in healthy and type 1 diabetic rat. Materials and methods: In this experimental study, sixty male wistar rats were randomly divided into 6 groups (n=10) and subjected to gavage tube therapy for one months by following protocol: group I and IV: diabetic control and non-diabetic control rats which only received distilled water; groups II and III: non diabetic treatment rats which received 200 mg/kg and 800 mg/kg CS extract per day respectively; groups V and VI: diabetic treatment rats which received 200 mg/kg and 800 mg/kg CS extract per day respectively. Diabetes was induced by intra-peritoneal injection of 50 mg/kg of streptozotocin (STZ). After 4 weeks, their blood were collected and the serum levels of creatinine, bilirubin, urea, uric acid, AST, ALT and ALP were measured. The liver, kidney, pancreas and stomach tissues were immediately excised, and after slide preparation processes, the histological changes were studied. Results: Our results illustrated that the gastric tissue in the diabetic group showed a small degree of changes and was not affected significantly by administration of the CS fruit extract. Liver, pancreas and kidney of diabetic rats exhibited considerable changes, like cellular necrosis. These changes in diabetic treatment groups were at lowest amounts. The decrease levels of creatinine, liver enzymes, and other factors were supporting these changes. Conclusions: This study demonstrates that the CS fruit extract could be aid prevention of damage to the tissues due to the decreased levels of harmful oxidants in the body in diabetes. Moreover, according to our previous results altogether we showed beneficial impact of the plant on the treatment of diabetes.

Influence of chronic comorbidity and medication on the efficacy of treatment in patients with diabetes in general practice

Evidence on the influence of comorbidity and comedication on clinical outcomes in patients with type 2 diabetes mellitus is scarce. To ascertain the effect of five chronic diseases (joint disorder, respiratory disease, anaemia, malignancy, depression) and three chronically used drugs (non-steroid anti-inflammatory drugs [NSAIDs], corticosteroids, antidepressants) on treatment for hypoglycaemia in patients with type 2 diabetes. Retrospective cohort study in a variety of practices across Flanders, Belgium. A retrospective cohort study was conducted, based on data from Intego, a general practice-based continuous morbidity registry. Multiple logistic regression analysis was used to predict the change in glycosylated haemoglobin (HbA1c) levels related to comorbidity, comedication, and a combination of both in 3416 patients with type 2 diabetes. Adjustments were made for age, sex, and diabetes-treatment group (diet, oral antidiabetic drugs, combination treatment, insulin). Concomitant joint and respiratory disorders, as well as the chronic use of NSAIDs and corticosteroids, either separately or in combination, were significantly associated with the worsening of HbA1c levels. Anaemia, depression, malignancy, and antidepressants had no statistically significant influence on the efficacy of treatment for hypoglycaemia. The presence of some comorbid diseases or drug use can impede the efficacy of treatment for type 2 diabetes. This finding supports the need to develop treatment recommendations, taking into account the presence of both chronic comorbidity and comedication. Further research must be undertaken to ascertain the effect other combinations of chronic diseases have on the efficacy of treatment of this and other diseases.